Semaine de la presse et des médias à l'école
Mardi 24 mars 2026
- Avec Créations, se présenter, prendre sa place.
- Avec JCoop, un défi maths.
- Avec BTj, découvrir une imprimerie et un journal télévisé.
www.icem-pedagogie-freinet.org/node/70184
#icem #freinet #jmag #jcoop #btj #creation #spme2026
C'est parti pour la Semaine de la presse et des médias à l'école avec les revues de l'ICEM...
Premier jour, lundi 23 mars 2026 :
- Avec CréAtions, des portraits.
- Avec BTj découvrir des journaux.
www.icem-pedagogie-freinet.org/node/70183
#icem #freinet #btj #creations #jmag #jcoop #smpe2026
From theory to practice: in #JCOOP, a conceptual model to describe how practices cope with losing a rural oncologist - and a new podcast interview with @fumikochino.bsky.social to really dive into a real-world example. #HealthPolicy
When an oncologist leaves a rural community, the vacancy is more than a line item on a HR report. A new #JCOOP study explores the repercussions of specialist scarcity.
Listen to the full podcast with @fumikochino.bsky.social, Dr. Erika Moen & Dr. Dan Zuckerman: ascopubs.org/do/understaf...
Fig 2. Constraints related to the patient, the pharmacy, and the outpatient infusion centers to be taken into account when concentrating outpatient ICI administrations in a stipulated time window in the morning. ICI, immune checkpoint inhibitor. Pharmacy constraints: physiochemical stability, risk of waste. Patient: distance home-hospital, diurnal preference. Day unit: priority rankings, long multi drug regimens.
Proposed Action We propose the following approaches to make early ToDA of ICI feasible in daily routine practice: • ASSESS: establish a nurse-led telephone assessment on the eve of ICI administration with full blood work-up available to confirm clinical and biologic permissiveness to ICI treatment; • AVOID (as far as possible and according to the habits of each center): do not schedule medical consultation and ICI treatment on the same day to reduce risks of delays in treatment administration (prefer teleconsultations the day before treatment for patients living far from the center); • ALWAYS administer ICI first when in combination with IV chemotherapy or other agents, unless reverse sequencing is recommended; • ALLOCATE: prioritize two or three ICI mornings per week and save the remaining two or three mornings for long-term combination treatments not including ICIs; • ANTICIPATE: whenever possible, cytotoxic reconstruction units could prepare ICIs in the evening of the eve so that they are ready to be administered early on the following morning.
🌅 Several studies have suggested checkpoint inhibitors dosed AM may be assoc w/ improved outcomes- but strong risk of confounding.
Out now in #JCOOP: review of literature & discussion of how practices could actually implement this. Suspect will be very dependent on local AM traffic!
Fig 1. (A and B) Thirty- and 90-day outcomes of intended complete treatment with histotripsy by histologic tumor treated and (C) time-to-event analysis for primary versus secondary malignancy. CCA, cholangiocarcinoma; CRLM, common cancer, with liver metastasis; HCC, hepatocellular carcinoma; HNSC, head and neck squamous cell; NET, neuroendocrine tumor; PDAC, pancreatic ductal adenocarcinoma.
What are outcomes w/ histotripsy for liver tumors/mets in real world since FDA approval in 12/2023? Out now in #JCOOP: at 3 mo, ~95% local control, 7% distant POD.
Need longer term data, not enough to distinguish b/w local control options, but helpful to have a start.
ascopubs.org/doi/10.1200/...
At first glance, Collineau's findings seem to be predictable: FOLFIRINOX is toxic, and OAs are vulnerable. But the deeper issue is whether we are asking the right question. By focusing narrowly on which OA can endure FOLFIRINOX, we risk missing the more relevant point: what is the most tolerable approach to the care of OAs with PDAC, and who truly benefits? The Edison analogy is instructive here. His lasting legacy was not the brightest bulb, but the system that made light usable, safe, and enduring. In PDAC, the lesson is similar: the discovery of an intense regimen is useless unless it is embedded in a system that makes treatment tolerable and meaningful for patients. For OAs, that grid is built through geriatric assessment (GA), supportive interventions (nutrition, prehabilitation, psychosocial support), and integration of palliative care.
From “Who Can Tolerate” to “Who Will Benefit” It is time for all of us to reimagine PDAC care in OA. The central question is no longer “who can tolerate FOLFIRINOX,” but “who will truly benefit?” Answering that requires 1. Routine GA to uncover vulnerabilities 2. Supportive interventions (comorbidity management, exercise, psychosocial support, nutritional support, and palliative integration) to enhance resilience 3. Trial designs that embed tolerability and quality of life as end points that complement response and survival 4. Exploration of objective aging biomarkers (inflammation, senescence, aging clocks, sarcopenia) for future stratification
Really important perspective from Ramy Sedhom on FOLFIRINOX in #panCAN patients >70 years old ("OA"). Even in selected patients who receive this intensive regimen, even w/ preemptive dose reductions, 56% G3 AE or unplanned hospitalization.
ascopubs.org/doi/10.1200/... #JCOOP #GIOnc
⏱️ Oncologists: save patients time & reduce infusion center overload - pembro in 10 minutes instead of 30. ⏱️
Safety data now out in #JCOOP, IRR low (4%) & similar to 30 min infusion. @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/min/1.73 m2
Estimated Glomerular Filtration Rate Equations Overestimate Renal Function Compared With Measured Glomerular Filtration Rate Using 24-Hour Urine Creatinine Clearance Full abstract beyond alt text limits but is available publicly at https://ascopubs.org/doi/10.1200/OP-25-00895 Highlighting Methods and Results: Methods In this prospective study, 72 patients with nonmetastatic RCC undergoing preoperative evaluation completed serum creatinine, cystatin C, and 24-hour urine collections. eGFR values were calculated using multiple established equations, both race-inclusive and race-neutral. The agreement between eGFR and measured GFR was assessed using Passing-Bablok regression. Linear regression estimated the discrepancy between eGFR and measured GFR at clinically relevant cutoffs of 45 and 60 mL/min/1.73 m2. Results Across all equations, eGFR consistently overestimated renal function compared with measured GFR. At a measured GFR of 45, corresponding eGFR values ranged from 53 to 59 mL/m
Significant overestimation of renal function by eGFR compared to measured CrCl in people with nonmetastatic RCC (including Cys C-adjusted).
Wide implications re: cystectomy cutoffs. #UroSky #NephSky is this part of your practice for people near cutoff?
ascopubs.org/doi/10.1200/... #MedSky #JCOOP
Table of employment and financial support recommendations from survivors by time period. Across the care continuum: Consider jobs that cover financial and insurance needs Set up a health savings account, contribute a small amount from each paycheck to help pay medical bills Ask for help from the care team, especially hospital social worker and use hospital billing department regarding cancer-related finances and resources Seek college scholarships During active therapy Explore short-term disability or other benefits offered by employer Consider ways to cut nonmedical expenses Seek financial assistance grants Set up a payment plan Learn/connect with other YAs on how they handled finances and cancer Early in survivorship Maintain employment with stable health insurance coverage Build financial literacy Seek vocational counseling to mitigate cancer-related job impacts Save money to account for rising cost of living and possible future medical costs
Saving, or “stockpiling” money (diagnosed 0-17 years; 21 years since diagnosis) was important to some interview participants on the basis of their cancer history, to cover future medical expenses, including the possibility of recurrence.
What financial advice do those who've survived AYA cancers give to people going through it now? In #JCOOP this week (among other insights), led by Tim Ohlsen @seattlechildrens.org
Notably, they highlight how much fear of future cost increases hangs over survivors.
ascopubs.org/doi/full/10....
Highlighted passage: Included in this study were patients with biopsy-confirmed mNSCLC who had not yet progressed or experienced serious adverse events to single-agent chemotherapy, and thus had reasonable options for further palliative systemic therapy. Patients must have been discharged to a SNF with an intention for further therapy once functional status permitted.
Fig 1. Sankey diagram depicting planned systemic therapy, proportion of patients who received said therapy, and treatment response. Chemo, any chemotherapy containing regimen; ICI, immune checkpoint inhibitor; TKI, tyrosine kinase inhibitor. Of the total 427 patients, 173 (40.5%) had a hospital readmission within the subsequent 30 days after discharge to a SNF. Only 229 (53.6%) ever managed to return to an outpatient oncology visit, and only 131 (30.7%) received any subsequent systemic therapy. This proportion varied by the intended therapy (Fig 1; Table 2), with 40 of the 54 planned for a TKI (74.1%), 42 of the 130 planned for ICI (32.3%), and 49 of the 243 planned for cytotoxic chemotherapy (20.2%) receiving further therapy (P < .001).
Wow. Data from @n8pennell.bsky.social & team #JCOOP confirming the care fragmentation many of us see in real life.
Patients with metastatic NSCLC whose docs felt it was reasonable for them to restart treatment after rehabbing at a SNF:
- Only 54% saw outpt onc again
- 31% restarted tx
Woah! 41% of stage I/IIA dMMR colon cancers could be overstaged by CT imaging. May need better ways to upfront stage (MRI, ctDNA?) in the neoadjuvant ICI era. #GIOnc #OncSky #MedSky #JCOOP
ascopubs.org/doi/10.1200/...
In Sept, Bishal Gyawali published in #JCOOP on the high cost of some 'more convenient' Rx formulations (peg-GCSF, oral GNRH instead of SQ/IM, combo pills)
Out now, European perspective on how to operationalize this:
ascopubs.org/doi/10.1200/...
Love to see an implementation win in @ascocancer.bsky.social/ #JCOOP ⬇️
In a mix of community/academic practices in NE, low overall inappropriate use of denosumab/zolendronic acid for mHSPC compared to prior national studies.
ascopubs.org/doi/10.1200/...
If you’re here at #ASCOQLTY25, stop by our tables to learn more about our offerings from Membership, #ASCOCertified & Quality Training Programs, and JCO Oncology Practice; take a survey about our mobile apps; and get freebies. 4th Floor, Grand Horizon Ballroom
#JCOOP
We're thrilled to be here on BlueSky to bring you the latest practice-changing oncology research from all six JCO Journals! Follow-us for great content from #JCO, #JCOOP, #JCOGO, #JCOPO, #JCOCCI, & #JCOOA.
Congratulations to @realbowtiedoc.bsky.social and @mazietsangmd.bsky.social on this excellent editorial highlighting the future of performance status assessment in oncology 👏 Thank you for the kind shout-out; honored to see our work cited #JCOOP @ascocancer.bsky.social
ascopubs.org/doi/10.1200/...
I am pleased to share a new article coauthored with a special friend, Dr. Karina Dahl Steffensen, Dean, Faculty of Medicine, Aalborg University, Denmark: ascopubs.org/doi/10.1200/...
#HenryFordHealth #AalborgUniversitet #shareddecisionmaking #SDM #cancercare #familycaregivers #JCOOP
‼️ #ASCO25 #JCOOP simultaneous publication by Kendzierski et al:
Remote Clinical Pharmacist Impact on Reducing Total Cost of Care in Enhancing Oncology Model-Enrolled Oncology Practices. Read the full article: brnw.ch/21wT6ul
‼️ #ASCO25 #JCOOP simultaneous publication by Velez et al:
Adequacy of Immune Checkpoint Inhibitor-Associated Thyroid Function Monitoring Following Therapy. Read the full article: brnw.ch/21wT6ov
Simultaneous Publication in #JCOOP. #ASCO25
Educational Impact of a Podcast Curriculum for Hematology/Oncology Fellows: Final Results of the Multicenter Cluster Randomized PODCAST-HOF Trial | JCO Oncology Practice ascopubs.org/doi/10.1200/...
www.cancertherapyadvisor.com/news/study-f... @brueraeduardo.bsky.social @mdanderson.bsky.social #jcoop
Opioid prescriptions for cancer pain have plunged 5 fold from 2016-2021! Under the mentorship of @brueraeduardo.bsky.social we spotlight the shifting trends in cancer pain management. Now in #JCOOP #ASCO.
🎙️In the latest #JCOOP podcast, @fumikochino.bsky.social discusses the past, present, and future of prior authorization in cancer care with Dr. Michael Anne Kyle, a health policy expert with a research focus on utilization management and patient burdens from prior auth. 🎧
ascopubs.org/do/prior-aut...
ICYMI: System-Level Transformations to Increase Patient Participation in Clinical Trials ascopubs.org/doi/10.1200/... #JCOOP
Cancer Patient Perspectives on Clinical Trial Discussion and Informed Consent Through Telemedicine ascopubs.org/doi/10.1200/...
#JCOOP
🎙️ new
@ascocancer.bsky.social #JCOOP podcast with Dr @michaelannica.bsky.social on #priorAuthorization
"I just think that there's a huge opportunity to do better here… I want to do better for our patients. I want to feel prouder of the healthcare system that I'm a part of." #fixPriorAuth
Opportunities for Artificial Intelligence in Oncology: From the Lens of Clinicians and Patients ascopubs.org/doi/10.1200/... #JCOOP #AI
From #JCOOP: “Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications.” ascopubs.org/doi/10.1200/...
